April 24th 2024
During a Case-Based Roundtable® event, Misako Nagasaka, MD, discussed treatment for a patient with non–small cell lung cancer and an EGFR exon 20 insertion.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
No PFS Improvement Is Seen With EGFR/VEGF Inhibitor Combo
September 20th 2020Patients with advanced lung adenocarcinoma who harbor EGFR T790M mutations did not experience significant progression-free survival improvement with osimertinib plus bevacizumab versus osimertinib alone, according to findings presented by Yukihiro Toi, MD, during the 2020 European Society for Medical Oncology Virtual Congress.
Read More
BLU-945 Shows Early Antitumor Activity in EGFR-Mutated NSCLC Models
September 20th 2020In preclinical models of triple-mutated EGFR-positive non–small cell lung cancer, the investigational agent, BLU-945 induced robust antitumor responses, according to results presented at the 2020 European Society of Medical Oncology Virtual Congress.
Read More
Clinical Trials Excite Treatment Landscape for Early-Stage EGFR-Mutated NSCLC
September 18th 2020Balazs Halmos, MD, MS, discusses 2 major presentations from the 2020 American Society of Clinical Oncology Virtual Scientific Program that appeared promising for the treatment of patients with EGFR-mutant non–small cell lung cancer.
Watch
Osimertinib Shows No OS Benefit Versus Chemotherapy in EGFR T790M-Mutant Advanced NSCLC Study
September 3rd 2020A statistically significant overall survival benefit was not observed with osimertinib compared with platinum-pemetrexed therapy as treatment of patients with EGFR T790M-mutated advanced non–small cell lung cancer.
Read More
Real-World Study Expands Benefit-Risk Assessment Data for Osimertinib in EGFR+ NSCLC
September 3rd 2020The benefits and risks of osimertinib as second- or later-line treatment of patients with EGFR-positive non–small cell lung cancer that were reported when the agent was first approved, have now been confirmed, according to data from a real-world study conducted in Japan.
Read More
GioTag Update: Final OS Promising for Sequential Afatinib Following Osimertinib in EGFR+ NSCLC
September 2nd 2020Sequential afatinib followed by osimertinib led to encouraging outcomes in patients with deletion 19 (del19) or L858R epidermal growth factor receptor (EGFR)-mutant non–small cell lung cancer, according to the final analysis results from the real-world study, GioTag.
Read More
Inferior Survival Outcomes Revealed in African American Patients with EGFR-Mutant NSCLC
August 27th 2020This is the first report to date that has demonstrated inferior survival outcomes among African American patients with NSCLC harboring an EGFR mutation relative to non-African American patients.
Read More
Indications Continue to Expand for EGFR Targeted Therapies in Lung Cancer
August 14th 2020Research into mutations in the gene encoding the epidermal growth factor receptor protein has revolutionized non–small cell lung cancer treatment in recent years, yet the science supporting targeting of this oncogene is still being elucidated.
Read More
NSCLC With EGFR Exon 20 Shows Benefit With Mobocertinib Over Chemotherapy
August 11th 2020Leora Horn, MD, MSc, discusses the data accrued from Flatiron and from a phase 1/2 trial of patients with refractory non–small cell lung cancer with EGFR exon 20 insertions receiving mobocertinib compared with currently approved therapies.
Watch
FDA Grants Breakthrough Therapy Designation to Osimertinib in EGFR+ Lung Cancer
July 30th 2020The FDA granted Breakthrough Therapy designation to osimertinib as adjuvant treatment of patients with stage IB-IIIA EGFR-mutated non–small cell lung cancer following complete tumor resection with curative intent.
Read More
Real-World Comparison Assesses Mobocertinib in NSCLC With EGFR Exon 20
July 29th 2020Leora Horn, MD, MSc, discusses the real-world data outcomes compared with clinical trial data of mobocertinib from a retrospective study in patients with refractory non–small cell lung cancer with EGFR exon 20 insertions.
Watch